The Role of Atorvastatin in Management of Eruptive Xanthoma on a Boy: A Case Report
DOI:
https://doi.org/10.3889/oamjms.2021.6941Keywords:
Case report, Eruptive xanthoma, Hypertriglyceridemia, AtorvastatinAbstract
Background: Eruptive xanthoma is a benign skin lesion caused by the accumulation of cholesterol and triglycerides in the skin's dermis. Xanthoma can be an early clinical manifestation of systemic diseases such as dyslipidemia, cardiovascular disease, diabetes mellitus. Clinical presentation varies from asymptomatic skin lesions to intense pruritus and tenderness.
Aim: This study aims that oral atorvastatin is effective in treating a child with eruptive xanthoma.
Case report: A three-year-old boy with an 8.4 kg body weight and 82.5 cm height came to the hospital with the chief complaint of small yellowish-white papules and nodes, discrete, 2-5 mm in size, painless on pressing, itchy, scattered, mainly in the lower extremity around the buttocks. On laboratory examination, Hb 11.5 g/dL, leukocyte 9,900/ul, platelet 413,000/uL, blood glucose 66 mg/dL. Further evaluation revealed total cholesterol 814 mg/dL, LDL 970 mg/dL, HDL 341 mg/dl, triglycerides 621 mg/dL; there is no evidence of familial hypercholesterolemia. The diagnosis is eruptive xanthoma. After starting treatment with atorvastatin 0.2 mg/kg body weight/day in one dose for six months, his cutaneous lesions gradually subsided and significantly decreased cholesterol, LDL, HDL, and triglyceride levels. Conclusion: Early therapy with atorvastatin will reduce the morbidity and mortality of eruptive xanthoma.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Kashif M, Kumar H, Khaja M. An unusual presentation of eruptive xanthoma: A case report and literature review. Medicine (Baltimore). 2016;95(37):e4866. https://doi.org/10.1097/md.0000000000004866 PMid:27631252 DOI: https://doi.org/10.1097/MD.0000000000004866
Zak A, Zeman M, Slaby A, Vecka M. Xanthomas: Clinical and pathophysiological relations. Biomed Pap. 2014;158(2):181-8. https://doi.org/10.5507/bp.2014.016 PMid:24781043 DOI: https://doi.org/10.5507/bp.2014.016
Crocker AC. Special reviews: Skin xanthomas in childhood. Pediatrics. 1951;8(4):573-97. PMid:14882914
Odeh AA. Xanthoma in a child as the first presentation of type one diabetes mellitus. Pediatr Ther. 2015;5:226.
Teltscher J, Silverman RA, Stork J. Eruptive xanthomas in a child with the nephrotic syndrome. J Am Acad Dermatol. 1989;21(5 Pt 2):1147-9. https://doi.org/10.1016/s0190-9622(89)70319-4 PMid:2808850 DOI: https://doi.org/10.1016/S0190-9622(89)70319-4
Parker F. Xanthomas and hyperlipidemias. J Am Acad Dermatol. 1985;13(1):1-30. PMid:4031142 DOI: https://doi.org/10.1016/S0190-9622(85)70139-9
Zaremba J, Zaczkiewicz A, Placek W. Eruptive xanthomas. Adv Dermatol Allergol. 2013;6(6):399-402. https://doi.org/10.5114/pdia.2013.39439 PMid:24494004 DOI: https://doi.org/10.5114/pdia.2013.39439
Maria VR, Maria OC. Dyslipidemia in Children with Acute Malnutrition. Turbo, Colombia. Perspect Nut Hum vol14 no2 Medellín July/Dec 2012; 2012.
Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Summary report. Pediatrics. 2011;128(Suppl 5):S213-56. https://doi.org/10.1542/peds.2009-2107c PMid:22084329 DOI: https://doi.org/10.1542/peds.2009-2107C
Nikolic D, Corina A, Toth PP, Hammad L, Rizzo M. Choosing an ideal pharmacotherapeutic strategy for dyslipidemia in children. Expert Opin Pharmacother. 2019;20(3):241-4. https://doi.org/10.1080/14656566.2018.1552942 PMid:30521406 DOI: https://doi.org/10.1080/14656566.2018.1552942
Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232(4746):34-47. https://doi.org/10.1126/science.3513311 PMid:3513311 DOI: https://doi.org/10.1126/science.3513311
Ness GC, Chambers CM, Lopez D. Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity. J Lipid Res. 1998;39(1):75-84. https://doi.org/10.1016/s0022-2275(20)34205-x PMid:9469588 DOI: https://doi.org/10.1016/S0022-2275(20)34205-X
Labos C, Brophy JM, Smith GD, Sniderman AD, Thanassoulis G. Evaluation of the pleiotropic effects of statins. Arterioscler Thromb Vasc Biol. Am Heart Assoc. 2018;38:262-5. DOI: https://doi.org/10.1161/ATVBAHA.117.310052
Khoury M, McCrindle BW. The rationale, indications, safety, and use of statins in the pediatric population. Can J Cardiol. 2020;36(9):1372-83. https://doi.org/10.1016/j.cjca.2020.03.041 PMid:32735868 DOI: https://doi.org/10.1016/j.cjca.2020.03.041
Luirink IK, Wiegman A, Kusters DM, Hof MH, Groothoff JW, de Groot E, et al. 20-year follow-up of statins in children with familial hypercholesterolemia. N Engl J Med. 2019;381(16):1547-56. https://doi.org/10.1056/nejmoa1816454 PMid:31618540 DOI: https://doi.org/10.1056/NEJMoa1816454
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Harapan Parlindungan Ringoringo (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
